Literature DB >> 10472350

Evaluation of chemotherapy response in patients with small cell lung cancer using Technetium-99m-tetrofosmin.

C H Kao1, Y J Ho, Y Y Shen, J K Lee.   

Abstract

The aim of this study was to investigate the relationship between Technetium-99m (Tc-99m) tetrofosmin accumulation in tumors which may represent the expression of multidrug resistance (MDR)--mediated P-glycoprotein (Pgp) and multidrug resistance-associated protein (MRP) as well as response to chemotherapy in patients with untreated small cell lung cancers (SCLC). Twenty patients with SCLC were studied with Tc-99m tetrofosmin lung scintigraphy before chemotherapeutic induction. Tc-99m tetrofosmin lung scans were interpreted both visually and quantitatively. Response was evaluated upon completion of chemotherapy. Patients with good chemotherapy response had a significantly higher incidence (93%) of positive Tc-99m tetrofosmin lung single photon emission computed tomography (SPECT) findings than patients with poor response (33%) (p value < 0.05). The tumor/background ratios (T/B) were 1.8 +/- 0.4 and 1.2 +/- 0.3, for patients with good response and poor response, respectively (p < 0.05). However, other prognostic factors (tumor size and stage) were not significantly related to Tc-99m tetrofosmin lung scan findings and chemotherapy responses. Tc-99m tetrofosmin lung scintigraphy can predict chemotherapy response in patients with SCLC.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10472350

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  3 in total

Review 1.  Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer.

Authors:  David J Stewart
Journal:  Crit Rev Oncol Hematol       Date:  2010-01-04       Impact factor: 6.312

2.  Noncardiac findings on dual-isotope myocardial perfusion SPECT.

Authors:  Kim A Williams; Kalisha A Hill; Candace M Sheridan
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

Review 3.  Transport processes of radiopharmaceuticals and -modulators.

Authors:  Thomas Efferth; Peter Langguth
Journal:  Radiat Oncol       Date:  2011-06-06       Impact factor: 3.481

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.